ReviewOncoimmunology2020
Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy.
Review in Oncoimmunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 141 citations in OpenAlex.
- Advances in vehicles for in situ delivery: From classical vectors to biologically inspired structures.Synthetic and systems biotechnology · 2026Review
- Extracellular vesicles: Navigating new frontiers in glioblastoma therapy.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- Spatiotemporally engineered tumor-derived extracellular vesicle-based scaffold vaccine for personalized cancer immunotherapy.Nature communications · 2026Article
- Extracellular vesicles in spine tumors: biological roles, immune modulation, and therapeutic implications.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026Review
- Precision Engineering of Extracellular Vesicles as Programmable Carriers for mRNA Therapeutics.International journal of nanomedicine · 2026Review
- Exploring tumor-derived exosomes as promising antigenic platforms: novel vaccine and immunotherapy strategies for "cold" colorectal cancer.Frontiers in immunology · 2026Review
- 80 years of extracellular vesicles: from discovery to clinical translation.Extracellular vesicles and circulating nucleic acids · 2026Review
- Cancer Vaccines: Molecular Mechanisms, Clinical Progress, and Combination Immunotherapies with a Focus on Hepatocellular Carcinoma.Current issues in molecular biology · 2025Review
- Innovations in cancer treatment as novel potential and the myth of personalized vaccines, immunotherapy, CRISPR/Cas9, and bacteriotherapy as promising therapeutic strategies.Discover oncology · 2025Review
- mRNA-Based Neoantigen Vaccines in Pancreatic Ductal Adenocarcinoma (PDAC)-A Promising Avenue in Cancer Immunotherapy.International journal of molecular sciences · 2025Review
- Innovative gene engineering and drug delivery systems for dendritic cells in cancer immunotherapy.Journal of biomedical science · 2025Review
- Exosomes in pancreatic islet biology and diabetes: Mechanisms, Biomarkers, and potential therapeutic perspectives.Journal of molecular histology · 2025Review
- The recent progress of tumor cell-derived exosomes in the pathogenesis, diagnosis and therapeutic strategies of tumors.Journal of translational medicine · 2025Review
- The Roles of Exosomes in Anti-Cancer Drugs.Cancer medicine · 2025Review
- Exosome-based cancer vaccine: a cell-free approach.Molecular biology reports · 2025Review
- Exosomes as key mediators in immune and cancer cell interactions: insights in melanoma progression and therapy.Archives of dermatological research · 2025Review
- Exosomes and solid cancer therapy: where are we now?Medical oncology (Northwood, London, England) · 2025Review
- Pre-injection of exosomes can significantly suppress ovarian cancer growth by activating the immune system in mice.Cancer immunology, immunotherapy : CII · 2025Article
- Tumor-derived exosomes as promising tools for cancer diagnosis and therapy.Frontiers in pharmacology · 2025Review
- Dendritic cell-based immunotherapy for head and neck squamous cell carcinoma: advances and challenges.Frontiers in immunology · 2025Review
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Identification of immunogenic tumor antigens that are efficiently processed and delivered by dendritic cells to prime the immune system and to induce an appropriate immune response is a research hotspot in the field of cancer vaccine development. High biosafety is an additional demand. Tumor-derived exosomes (TEXs) are nanosized lipid bilayer encapsulated vesicles that shuttle bioactive information to the tumor microenvironment facilitating tumor progression. However, accumulating evidence points toward the capacity of TEXs to efficiently stimulate immune responses against tumors provided they are appropriately administered. After briefly describing the function of exosomes in cancer biology and their communication with immune cells, we summarize in this review
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.